BioSpace News Archive

New Company Advances Therapies to Address Unmet Medical Needs of Parkinson’s Disease

DNA Script today announced that the company and its Molecular Encoding Consortium partners have been awarded a multi-phase contract worth up to $23 million from the Intelligence Advanced Research Projects Activity’s (IARPA) Molecular Information Storage (MIST) program

EOS imaging (Paris:EOSI) (Euronext, FR0011191766 - EOSI - Eligible PEA - PME), a leader in 2D/3D orthopedic medical imaging and software solutions for 3D anatomical modeling and surgical planning, today announces its unaudited full-year sales for the financial year ending December 31, 2019.

INTELLiSTEM Technologies, an international biotechnology company revolutionizing cell therapy, announces today the launch of IntelliPeptidomeTM, a novel Drug Discovery Platform for rapid and systematic identification of MHC/HLA bound peptide candidates for various clinical applications.

UCB Canada Inc. announced today that Health Canada has approved CIMZIA® (certolizumab pegol) for the treatment of adults with severe active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and / or magnetic resonance imaging (MRI) evidence who have had an inadequate response to, or are intolerant to nonsteroidal anti-inflammatory drugs (NSAIDs).

Health New England released data showcasing results from its medical pharmacy program focused on biosimilar management in collaboration with Magellan Rx Management.

Findings from the latest edition of the PMPRB’s Meds Entry Watch report show a continued rise in the number of new specialized treatments entering international markets.

EVONETIX LTD (‘Evonetix’), the synthetic biology company developing a desktop platform for scalable, high-fidelity and rapid gene synthesis, today announced it has partnered with imec, a world-leading research and innovation hub active in the fields of nanoelectronics and digital technologies, to increase production of Evonetix’s proprietary microelectromechanical systems (MEMS)-based silicon chips, enabling the platform to be manufactured at a commercial scale.

CARB-X is awarding Trellis Bioscience, of Redwood City, California, USA, up to $3.2 million in non-dilutive funding, with the possibility of $3.8 million more if certain project milestones are met, to develop an innovative monoclonal antibody designed to disrupt the protective biofilm that makes bacteria resistant to antibiotics.

Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a British medical technology company that has developed a personal haemodialysis system called SC+, today announces it has entered into an agreement with B. Braun Avitum UK Ltd (“B. Braun”) to provide products and support services to Quanta’s UK patients using SC+ at home